US News

Pfizer, BioNTech report high efficacy of COVID-19 booster shot in study

Published by
Reuters

BERLIN (Reuters) – Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant. They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent. The study also found that the booster shot had a favourable safety profile. Pfizer had said its two-shot vaccine’s efficacy drops over time, citing a study that showed 84% effectiveness from a peak of 96% four month…

Read More

Facebook Comments

Check Also

Bach says Peng offered help ‘in all areas’, Games cannot change China

Published by DPA International Olympic Committee president Thomas ...

Archives